Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
The goal of this research study is to identify biologic and lifestyle factors that may increase a person's risk of developing a recurrence (return) of colon cancer.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Prognostic Molecular and Environmental Factors in High-Risk Stage II and Stage III Colon Cancer Patients|
- Occurence of Recurrent Colon Cancer [ Time Frame: Information collected at 1, 2 and 3 years after completion of adjuvant chemotherapy or at the time of reoccurrence. ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
20 ml of blood for genomic analysis collected at baseline, at completion of adjuvant chemotherapy ( <28 days after its completion) if applicable, at each subsequent surveillance visit (every 3 months after discontinuation of adjuvant chemotherapy, continuing for 2 years), and at time of disease recurrence, if applicable.
20 ml of blood for proteomic analysis studies collected at baseline, at completion of adjuvant chemotherapy, if applicable ( <28 days after its completion), and at time of disease recurrence, if applicable.
Tissue (0.2gm of tissue) from primary resection obtained at time of study enrollment. A tissue sample (0.2gm of tissue) also obtained, if possible, from patients that require surgical intervention at M.D. Anderson Cancer Center, for recurrent disease.
|Study Start Date:||January 2006|
|Estimated Primary Completion Date:||January 2016 (Final data collection date for primary outcome measure)|
Colon Cancer Patients
Patients with colon cancer recently removed by surgery.
Two questionnaires taking 30 minutes to complete.
Other Name: Survey
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00354705
|Contact: Cathy Eng, MD||713-792-2828|
|United States, Texas|
|UT MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Cathy Eng, MD||M.D. Anderson Cancer Center|